{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T20:03:35Z","timestamp":1776629015468,"version":"3.51.2"},"reference-count":50,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2016,2,23]]},"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Agalsidase \u03b2 is a form of enzyme replacement therapy for Fabry disease, a genetic disorder characterised by low \u03b1-galactosidase A activity, accumulation of glycosphingolipids and life-threatening cardiovascular, renal and cerebrovascular events. In clinical trials, agalsidase \u03b2 cleared glycolipid deposits from endothelial cells within 6\u2005months; clearance from other cell types required sustained treatment. We hypothesised that there might be a \u2018lag time\u2019 to clinical benefit after initiating agalsidase \u03b2 treatment, and analysed the incidence of severe clinical events over time in patients receiving agalsidase \u03b2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The incidence of severe clinical events (renal failure, cardiac events, stroke, death) was studied in 1044 adult patients (641 men, 403 women) enrolled in the Fabry Registry who received agalsidase \u03b2 (average dose 1\u2005mg\/kg every 2\u2005weeks) for up to 5\u2005years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The incidence of all severe clinical events was 111 per 1000 person-years (95% CI 84 to 145) during the first 6\u2005months. After 6\u2005months, the incidence decreased and remained stable within the range of 40\u201358 events per 1000 patient-years. The largest decrease in incidence rates was among male patients and those aged \u226540\u2005years when agalsidase \u03b2 was initiated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Contrary to the expected increased incidence of severe clinical events with time, adult patients with Fabry disease had decreased incidence of severe clinical events after 6\u2005months treatment with agalsidase \u03b2 1 mg\/kg every 2\u2005weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>NCT00196742.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jmedgenet-2015-103486","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T00:00:55Z","timestamp":1458345655000},"page":"495-502","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":130,"title":["Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry Registry"],"prefix":"10.1136","volume":"53","clinical-trial-number":[{"clinical-trial-number":"nct00196742","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00196742","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alberto","family":"Ortiz","sequence":"first","affiliation":[{"name":"Unidad de Dialisis, IIS-Fundacion Jimenez Diaz\/UAM, IRSIN, Madrid, Spain"}]},{"given":"Ademola","family":"Abiose","sequence":"additional","affiliation":[{"name":"North Ohio Heart Center, Westlake, Ohio, USA"}]},{"given":"Daniel G","family":"Bichet","sequence":"additional","affiliation":[{"name":"H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al and University of Montreal, Montreal, QC, Canada"}]},{"given":"Gustavo","family":"Cabrera","sequence":"additional","affiliation":[{"name":"Grupo Medico Del Viso, Buenos Aires, Argentina"}]},{"given":"Joel","family":"Charrow","sequence":"additional","affiliation":[{"name":"Division of Genetics, Birth Defects, and Metabolism, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA"},{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}]},{"given":"Dominique P","family":"Germain","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, University of Versailles\u2014St Quentin en Yvelines, Versailles, France"},{"name":"Assistance Publique\u2014H\u00f4pitaux de Paris, Garches, France"}]},{"given":"Robert J","family":"Hopkin","sequence":"additional","affiliation":[{"name":"Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA"}]},{"given":"Ana","family":"Jovanovic","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Medicine, Salford Royal NHS Foundation Trust, Salford, UK"}]},{"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Charles University, Prague, Czech Republic"}]},{"given":"Sonia S","family":"Maruti","sequence":"additional","affiliation":[{"name":"Genzyme, a Sanofi Company, Cambridge, Massachusetts, USA"}]},{"given":"Michael","family":"Mauer","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, Minnesota, USA"}]},{"given":"Jo\u00e3o P","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Department of Genetics, S\u00e3o Jo\u00e3o Hospital Centre & Faculty of Medicine, University of Porto, Porto, Portugal"},{"name":"I3S\u2014Institute for Research and Innovation in Health, University of Porto, Porto, Portugal"}]},{"given":"Manesh R","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Duke University School of Medicine, Durham, North Carolina, USA"}]},{"given":"Juan","family":"Politei","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fundacion Para el Estudio de Enfermedades Neurometabolicas (FESEN), Buenos Aires, Argentina"}]},{"given":"Stephen","family":"Waldek","sequence":"additional","affiliation":[{"name":"University of Sunderland, Sunderland, UK"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Clinic, University of W\u00fcrzburg, W\u00fcrzburg, Germany"}]},{"given":"Han-Wook","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea"}]},{"given":"David G","family":"Warnock","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}]}],"member":"239","published-online":{"date-parts":[[2016,3,18]]},"reference":[{"key":"2025101723202892000_53.7.495.1","unstructured":"Desnick RJ , Ioannou YA , Eng CM . Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR , Beaudet AL , Valle D , Sly WS , Childs B , Kinzler KW , Vogelstein B , eds. The metabolic & molecular bases of inherited disease. 8th edn. New York, NY: McGraw-Hill, 2001:3733\u201374."},{"key":"2025101723202892000_53.7.495.2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-30"},{"key":"2025101723202892000_53.7.495.3","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e318183f132"},{"key":"2025101723202892000_53.7.495.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.11.018"},{"key":"2025101723202892000_53.7.495.5","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.526293"},{"key":"2025101723202892000_53.7.495.6","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp554"},{"key":"2025101723202892000_53.7.495.7","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2008.065904"},{"key":"2025101723202892000_53.7.495.8","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181bb05bb"},{"key":"2025101723202892000_53.7.495.9","doi-asserted-by":"publisher","DOI":"10.1111\/cge.12613"},{"key":"2025101723202892000_53.7.495.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450102"},{"key":"2025101723202892000_53.7.495.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2743"},{"key":"2025101723202892000_53.7.495.12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00675.x"},{"key":"2025101723202892000_53.7.495.13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.841494"},{"key":"2025101723202892000_53.7.495.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2004.01309.x"},{"key":"2025101723202892000_53.7.495.15","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-007-0521-2"},{"key":"2025101723202892000_53.7.495.16","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-014-9677-8"},{"key":"2025101723202892000_53.7.495.17","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-47"},{"key":"2025101723202892000_53.7.495.18","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12077"},{"key":"2025101723202892000_53.7.495.19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs526"},{"key":"2025101723202892000_53.7.495.20","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/3.4.667"},{"key":"2025101723202892000_53.7.495.21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","article-title":"Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes","volume":"3","author":"Eng","year":"1997","journal-title":"Mol Med"},{"key":"2025101723202892000_53.7.495.22","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/3.10.1795"},{"key":"2025101723202892000_53.7.495.23","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000012626.81324.38"},{"key":"2025101723202892000_53.7.495.24","first-page":"784","article-title":"Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease","volume":"47","author":"Sakuraba","year":"1990","journal-title":"Am J Hum Genet"},{"key":"2025101723202892000_53.7.495.25","doi-asserted-by":"publisher","DOI":"10.1086\/504601"},{"key":"2025101723202892000_53.7.495.26","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2011.31"},{"key":"2025101723202892000_53.7.495.27","unstructured":"Fabry disease mutation database (H. Sakuraba). http:\/\/fabry-database.org\/mutants\/ (accessed 1 Dec 2015)."},{"key":"2025101723202892000_53.7.495.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2014.11.004"},{"key":"2025101723202892000_53.7.495.29","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2013-101857"},{"key":"2025101723202892000_53.7.495.30","doi-asserted-by":"publisher","DOI":"10.1002\/humu.10275"},{"key":"2025101723202892000_53.7.495.31","unstructured":"Szklo M , Nieto FJ . Epidemiology: beyond the basics. 1st edn. Gaithersburg, MD: Aspen Publishers, 2000:55\u201389."},{"key":"2025101723202892000_53.7.495.32","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-2-200701160-00148"},{"key":"2025101723202892000_53.7.495.33","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000221212.36860.c9"},{"key":"2025101723202892000_53.7.495.34","doi-asserted-by":"publisher","DOI":"10.1159\/000209260"},{"key":"2025101723202892000_53.7.495.35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31826e9af8"},{"key":"2025101723202892000_53.7.495.36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.8777"},{"key":"2025101723202892000_53.7.495.37","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.05.017"},{"key":"2025101723202892000_53.7.495.38","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2014-102797"},{"key":"2025101723202892000_53.7.495.39","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2013.53"},{"key":"2025101723202892000_53.7.495.40","doi-asserted-by":"publisher","DOI":"10.1159\/000369293"},{"key":"2025101723202892000_53.7.495.41","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr420"},{"key":"2025101723202892000_53.7.495.42","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462314000762"},{"key":"2025101723202892000_53.7.495.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61407-5"},{"key":"2025101723202892000_53.7.495.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111732"},{"key":"2025101723202892000_53.7.495.45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282612"},{"key":"2025101723202892000_53.7.495.46","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070640"},{"key":"2025101723202892000_53.7.495.47","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080816"},{"key":"2025101723202892000_53.7.495.48","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012030316"},{"key":"2025101723202892000_53.7.495.49","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0253-6"},{"key":"2025101723202892000_53.7.495.50","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014121226"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmedgenet-2015-103486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T06:20:39Z","timestamp":1760768439000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmedgenet-2015-103486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,18]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,6,23]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1136\/jmedgenet-2015-103486"],"URL":"https:\/\/doi.org\/10.1136\/jmedgenet-2015-103486","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,18]]}}}